Opendata, web and dolomites

3DPD

PhD position in commercial environment: cancer immunotherapy drug screening in 3D

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "3DPD" data sheet

The following table provides information about the project.

Coordinator
OCELLO BV 

Organization address
address: J.H OORTWEG 21
city: LEIDEN
postcode: 2333 CH
website: www.ocello.nl

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Project website https://www.linkedin.com/feed/update/urn
 Total cost 134˙625 €
 EC max contribution 134˙625 € (100%)
 Programme 1. H2020-EU.2.3.2.2. (Enhancing the innovation capacity of SMEs)
 Code Call H2020-INNOSUP-02-2016
 Funding Scheme CSA
 Starting year 2017
 Duration (year-month-day) from 2017-09-01   to  2018-08-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    OCELLO BV NL (LEIDEN) coordinator 134˙625.00

Map

 Project objective

OcellO B.V., a Dutch SME, is recruiting an Immuno-Oncology Innovation Associate to support the diversification of its portfolio of innovative services. OcellO is a contract research organization (CRO) that delivers supreme in vitro screening tools for drug developers. The SME has a number of high-throughput screening tools on the market, all of which are based on its proprietary 3D cell culture technique with concomitant imaging and analyses tools. Currently, OcellO is growing so-called ‘organoids’ composed of a single cell type. The different screening tools it now has on the market each make use of a single cell type of different origin.

Strengthened by the needs expressed by the market, OcellO wants to expand its portfolio with the delivery of 3D cultures based on two or more different cell types combined in one organoid. The primary focus for this project is on combining cancer cells with cells from the immune system, to support the development of immuno-modulating cancer drugs – a highly promising field of anti-cancer drug development. There is a high unmet need for affordable and meaningful screening technologies for the selection of the most promising drugs for clinical development from a vast number of promising compounds designed for stimulating our immune system to eradicate cancer cells. None of the screening tools currently available can deliver on the needs of the industry.

For the development of its first screening platform based on the co-culture of cells in 3D, OcellO is eager to hire a post-doc level, established researcher (R3). The Immuno-Oncology Innovation Associate has a PhD in immunology and experience in oncology. (S)he has affinity with cell biology, fluorescence imaging, and with exploitation of technology. In the competitive Dutch employment environment, it is hard for OcellO to compete for the top researchers. With EU support, OcellO can target a larger market and offer a truly competitive package of remuneration and fringe benefits.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "3DPD" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "3DPD" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.2.3.2.2.)

bsnEA (2020)

Business Support Network – East Anatolia

Read More  

PROBIM (2020)

PRO Business Innovation Moldova

Read More  

MontEENegro (2020)

Enhancing innovation management capacities of SMEs in Montenegro

Read More